Qilu Pharmaceutical Co., Ltd.
Clinical trials sponsored by Qilu Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cheaper cancer drug on the horizon? new biosimilar QL2109 tested in healthy men Results expected Sep 2026 (estimated)
- New drug combo shows promise for Hard-to-Treat cancers Results expected Oct 2026 (estimated)
- New hope for bile duct cancer: experimental drug combo enters Mid-Stage trial Results expected Oct 2026 (estimated)
- New pill QLS-1304 enters human testing for advanced cancers Results expected Nov 2026 (estimated)
- New daily pill could ease heavy periods from fibroids Results expected Nov 2026 (estimated)
-
Can a pill replace injections to fight advanced prostate cancer?
Disease control CompletedThis Phase 3 trial tests an oral drug called QLG1080 in men with hormone-sensitive advanced prostate cancer. The goal is to see if the drug can safely lower testosterone to castration levels, which helps slow cancer growth. Participants must be eligible for endocrine therapy and …
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug aims to stop chemo sickness in its tracks
Symptom relief CompletedThis study tested a new medicine called QLM2010 to see if it can prevent nausea and vomiting caused by strong chemotherapy. 665 adults with solid tumors who had never had chemo before took part. The goal was to see if QLM2010 works better than current standard drugs at stopping v…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Healthy volunteers test new MASH drug in early safety trial
Knowledge-focused CompletedThis early-stage study tests the safety and tolerability of a new drug called QL2401 in 70 healthy Chinese adults aged 18 to 45. Participants receive either the drug or a placebo to see how the body handles it. The goal is to gather initial safety data before testing in people wi…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Healthy volunteers help test copycat drug against approved biologic
Knowledge-focused CompletedThis study tests a new drug called QL2106 against an approved drug, Tremfye® (guselkumab), in 190 healthy adults aged 18-45. The goal is to compare how the body processes each drug, their safety, and immune response after a single dose. Participants receive one injection and are …
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC